Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
C$0.16
+3.2%
C$0.17
C$0.07
C$0.28
C$8.53M1.5821,591 shs500 shs
Viela Bio, Inc. stock logo
VIE
Viela Bio
$53.01
$53.01
$25.02
$65.00
$2.91B0.431.07 million shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
0.00%-5.88%+10.34%0.00%+23.08%
Viela Bio, Inc. stock logo
VIE
Viela Bio
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
N/AN/AN/AN/AN/AN/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
0.00
N/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
N/AN/AC$0.05 per share3.31C$0.10 per shareN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
$50M58.26N/AN/A$7.14 per share7.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
-C$1.63M-C$0.03N/AN/AN/A-25.87%-18.08%N/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
N/AN/AN/AN/AN/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
0.18
2.86
6.40
Viela Bio, Inc. stock logo
VIE
Viela Bio
N/A
19.51
19.49

Institutional Ownership

CompanyInstitutional Ownership
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
N/A
Viela Bio, Inc. stock logo
VIE
Viela Bio
46.98%

Insider Ownership

CompanyInsider Ownership
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
47.90%
Viela Bio, Inc. stock logo
VIE
Viela Bio
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Karnalyte Resources Inc. stock logo
KRN
Karnalyte Resources
153.28 millionN/ANot Optionable
Viela Bio, Inc. stock logo
VIE
Viela Bio
16654.95 millionN/ANot Optionable

Recent News About These Companies

BETDAQ app download
dc vs punjab 2022
Khelo India Khelo lucky 3 result today
777 Win Sooter
RGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-Dollar
Roche takes on Alexion as FDA approves satralizumab in NMOSD
Regenxbio Names Mitchell Chan CFO
2024 Fire Awards: Meet this year's Ablaze honorees

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Karnalyte Resources stock logo

Karnalyte Resources TSE:KRN

C$0.16 +0.01 (+3.23%)
As of 06/27/2025 10:24 AM Eastern

Karnalyte Resources Inc is a development stage company focused on two fertilizer products, potash and nitrogen, to be produced and manufactured in Saskatchewan. It owns the construction ready Wynyard Potash Project, with planned phase 1 production of high grade granular potash, and two subsequent phases. It is also exploring the development of the Proteos Nitrogen Project, which is a proposed small-scale nitrogen fertilizer plant with a nameplate production capacity of approximately 700 metric tonnes per day of ammonia and approximately 1,200 MTPD of urea, and a target customer market of independent fertilizer wholesalers in Central Saskatchewan.

Viela Bio stock logo

Viela Bio NASDAQ:VIE

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.